You are here

Embattled Theranos Voids Two Years of Blood Test Results

Company revises tens of thousands of analyses

Embattled blood-testing company Theranos Inc. has informed health regulators at the Centers for Medicare and Medicaid Services (CMS) that it has dumped all of the results obtained with its Edison testing devices in 2014 and 2015, according to a report in the Wall Street Journal. The company also disclosed that it has issued tens of thousands of corrected blood-test reports to doctors and patients, voiding some results and revising others.

The moves are seen as attempts by Theranos to persuade the CMS not to impose stiff sanctions that the agency threatened in the aftermath of its inspection of the company’s Newark, California, laboratory. Company records reviewed during that inspection showed that the laboratory ran approximately 890,000 tests a year. The inspectors found that the Edison machines in the lab often failed to meet the company’s own accuracy requirements.

Theranos also told the CDC that it used the Edison devices for only 12 types of tests out of more than 200 offered to consumers and stopped using the machines altogether in late June 2015. Theranos had touted the devices as revolutionary, leading to a $9 billion valuation of the company in 2014.

In March 2016, the CMS proposed banning Theranos founder Elizabeth Holmes from the blood-testing business for at least two years after concluding that the company failed to fix what regulators called major problems at the California lab. The CMS also threatened to revoke the California lab’s federal license and to impose hefty fines against Theranos.

Last week, Theranos announced the departure of Sunny Balwani, its No. 2 executive, who also was under the threat of a two-year ban from the blood-testing industry.

Source: Wall Street Journal; May 18, 2016.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs